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Abstract
Background: After the largest outbreaks of Q fever ever recorded in history occurred in the Netherlands, concern
arose that Coxiella may be transmitted via donated tissues of latent or chronically infected donors. The Dutch
Health Council recently advised to screen tissue donors, donating high risk tissues, for Coxiella infection.
Methods: After validation of an enzyme immunoassay (EIA) test for IgG antibodies against phase 2 of C. burnetii for
use on post-mortem samples, serum samples of 1033 consecutive Dutch post-mortem tissue donors were tested
for IgG antibodies against phase 2 of C. burnetii. Confirmation of reactive results was done by immunofluorescence
assay (IFA). All available tissues (corneas, heart valves, skin and bone marrow) from donors with IgG reactivity were
tested for presence of Coxiella DNA by PCR. Risk factors for IgG reactivity were investigated.
Results: After validation of the tests for use on post-mortem samples, 50/1033 donors (4.8%) screened positive for
phase 2 anti-Coxiella IgG by EIA, and 31 were confirmed by IFA (3.0%). One donor showed a serological profile
compatible with chronic infection. All tested tissues (25 corneas, 6 heart valves, 4 skin and 3 bone marrow) from
donors with IgG reactivity tested negative for the presence of Coxiella DNA. Except for living in a postal code area
with a high number of Q fever notifications, no risk factors for IgG reactivity were found.
Conclusions: The strong correlation between notifications and seroprevalence confirms that the used assays are
sufficiently specific for use on post-mortem samples, although one has to be aware of differences between batches.
Thus, this study provides a validated method for screening tissue donors for infection with Coxiella burnetii that can
be used in future outbreaks.
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Background
Q fever is a zoonotic disease caused by infection with
the bacterium Coxiella burnetii. Airborne transmission
from infected goats and sheep is the principle mode of
transmission to humans. In the Netherlands Q fever out-
breaks started in 2007 and increased in the subsequent
years. Over 4000 cases and 25 casualties were reported
between 2007 and 2010, making it the largest Q fever
epidemic ever reported. After various measures were
taken, including culling of pregnant goats at infected
farms, the number of reported cases declined in 2010
and returned to less than 100 cases per year in 2011.
Most Coxiella infections pass asymptomatic (± 60%),
but mild flu-like illness or severe disease with pneumo-
nia or hepatitis occurs. Current data suggest that 1.5 to
2% of infected persons develop chronic Q fever, most
often persons with underlying (cardiovascular) disease
or immunocompromised individuals [1]. Chronic Q
fever often presents as endocarditis, but currently in
the Netherlands many cases of vascular infections occur
[2]. Estimates of the case fatality rate for chronic Q fever
vary from 5 to 50%, depending on clinical manifestations
and treatment options [3].* Correspondence: m.vanwijk@bislife.org
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In literature, no C. burnetii transmission through
tissue transplantation has been described, but single ca-
ses of transmission through blood transfusion [4] and
through bone marrow transplantation to an immuno-
compromised recipient [5] were reported as well as
transmission through organ transplantation in animals
[6]. C. burnetii has been shown to persist in various tis-
sues after acute infection, most notably in bone marrow
[7,8]. C. burnetii will not be detected by microbiological
cultures, as employed in tissue banks. A pilot study indi-
cated that serological testing on post-mortem blood is
possible, with the test showing sufficient sensitivity and
specificity to proceed to a larger scale of testing. C. bur-
netii is not rendered harmless by storage, even at low
temperatures, but some processing techniques may have
a sterilising effect, e.g. glycerolisation, alcoholisation,
peracetic acid treatment, irradiation or decellularisation.
Different tissues may pose different risks, with heart
valves and bone (in which Coxiella may grow during
chronic infection) probably posing the highest risk [9].
The tissue with the lowest transmission risk through
transplantation is probably cornea, which is avascular,
and no Q fever symptoms have been described in the
anterior eye [9].
With progression of the Dutch outbreak, the risk of
transmitting C. burnetii through tissue transplantation
was minimized by implementing control measures based
on a risk assessment [9]. These included exclusion of do-
nors with increased risk of acute or chronic Q fever,
based on occupational and geographical risk factors, and
on clinical presentation and medical history. Further-
more, the possibility for serological testing was investi-
gated as well as processing strategies that can render the
bacteria harmless. Currently, the Dutch Health Council
has advised to screen tissue donors (with the exception
of cornea donors) for signs of current or past infection
with C. burnetii, the major concern after the outbreaks
being that tissues from donors with chronic Q fever
might be infectious [10]. The current study was under-
taken prior to this advice with the following aims:
 Validation of a serological test for use with post-
mortem samples and estimation of the seroprevalence
of C. burnetii infection in Dutch tissue donors.
 To determine whether C. burnetii DNA can be
detected in tissues for transplantation (cornea with
scleral rim, skin, heart valves, bone marrow) after
Coxiella infection.
This study provides information on which donor se-
lection policies for tissue transplantation can be based,
with an optimal balance between donor safety and tissue
availability, providing a screening system that can be used
during outbreaks of Q fever.
Methods
Donor serum samples
Serum samples were included from all Dutch post-
mortem tissue donors between October 2010 and June
2011, from whom at least one tissue was approved at ini-
tial assessment. All serum samples were obtained within
24 hours post-mortem, unless there was haemodilution or
insufficient quality, in which cases (pre-transfusion) ante-
mortem samples were used for testing. Standard donor se-
lection criteria were applied during the study. Regarding
Q fever the following donors were excluded: donors with
proven acute Q fever; donors with signs of acute Q fever
(such as flu-like symptoms, pneumonia without a clear
cause or identified pathogen or hepatitis); and donors with
a high risk of acute or chronic Q fever, such as donors
with occupational hazard (i.e. farmers and veterinarians).
Donor tissue samples
Tissue samples from all donors who tested positive for
IgG antibodies against phase 2 of C. burnetii were col-
lected and stored for detection of Coxiella DNA (provided
that permission for transplantation-related research had
been given).
Detection of Coxiella antibodies
Serum samples from the post-mortem tissue donors
were tested for IgG antibodies against phase 2 of C.
burnetii using the CE-marked Serion enzyme immuno-
assay (EIA) test (Serion, Clindia Benelux, Leusden, the
Netherlands). The cut-off values for EIA (borderline) po-
sitivity were determined according to the manufacturer’s
instructions. Borderline reactive samples were consi-
dered positive. Confirmation of positive samples was
performed using an immunofluorescence assay (IFA) for
IgG antibodies against phase 1 and 2 of C. burnetii
(Focus Diagnostics, Cypress, CA) following instructions
of the manufacturer, using a cutoff dilution of 1:32. An
IgG phase 1 antibody titer ≥ 1/1024 was considered
suspect for chronic Q fever [11-13]. Both serologic
tests have, to our knowledge, never been used for post-
mortem blood samples. Cadaveric specimens are of lower
quality than regular blood samples, showing more false-
positive and false-negative reactions. Validation of the EIA
and the IFA was therefore performed prior to the start of
the study.
The Serion anti-Coxiella phase 2 IgG EIA was vali-
dated by testing 45 randomly selected donated post-
mortem samples. One of the 45 samples tested positive;
this result was confirmed by IFA. The average EIA signal
(measured as the optical density signal to cutoff ratio)
was not different between negative post-mortem samples
and negative samples from 92 healthy blood donors
from the Northwestern part of the country (OD/CO
0.107 ± 0.112 versus 0.104 ± 0.008, p = 0.87). The clinical
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specificity in post-mortem samples could not be deter-
mined, since no samples from post-mortem tissue do-
nors historically proven to be reactive were available.
Effects of the cadaveric nature of the samples on the
sensitivity were assessed by spiking samples. A panel of
20 samples from post-mortem tissue donors, showing
various degrees of haemolysis, was spiked with 1/8 vol-
ume of serum from a healthy blood donor who tested
positive for both anti-Coxiella phase 1 and 2 IgG [14].
The average increase in OD caused by the spiking was
slightly higher for post-mortem samples than for sera
from 18 healthy blood donors (ΔOD= 0.556 ± 0.075 ver-
sus 0.486 ± 0.080, respectively; p = 0.009). The signal in-
crease was not significantly different in hemolytic samples
compared to normal post-mortem samples, suggesting the
EIA test is sufficiently robust for measuring post-mortem
samples of relatively low quality.
A small-scale validation of the IFA for measuring post-
mortem serum samples was performed by measuring 27
random post-mortem samples. All samples tested nega-
tive and no high background fluorescence was observed.
Further validation was done by spiking samples suspec-
ted to be false-positive in the EIA (see results section).
18 samples with a varying degree of EIA reactivity that
were not confirmed by IFA were spiked with 1/8 volume
of serum from a healthy blood donor positive for phase
1 and 2 IgG. The fluorescence intensity after spiking did
not significantly differ between EIA-negative samples,
borderline-positive samples and IEA-positive samples,
suggesting that the negative IFA results (of the unspiked
samples) were not caused by signal inhibition.
Detection of Coxiella DNA
Donated tissues from donors positive for C. burnetii
antibodies were tested for the presence of C. burnetii
DNA by PCR. Corneas were frozen at −20°C until ana-
lysis as soon as serology results were known. For cornea
donors, a wedge of cornea, including scleral rim, was
used for DNA extraction and PCR testing. For skin do-
nors, skin samples, frozen in an 85% glycerol buffer, and
skin storage solution were tested. For heart valve donors,
aortic and pulmonary valves, aortic and pulmonary ar-
tery wall and myocardium were tested. If available,
samples were used from cryopreserved grafts, stored for
transplantation. If no grafts for transplantation were
available, sampling was done from formaldehyde-fixed
remnants of the heart that are routinely stored for histo-
logical examination. These samples were embedded in
paraffin and cut into ribbons before DNA extraction.
For musculoskeletal tissue donors, bone marrow samples
were taken at retrieval and stored at −20°C for PCR
testing.
To efficiently extract DNA from tissues, proteinase K
digestion was performed prior to DNA extraction. One
fourth of the cornea, ±50-100 mm3 of skin tissue, heart
valve tissue or bone marrow was digested with 25 μL
of proteinase K (20 mg/ml; Roche Diagnostics GmbH,
Mannheim, Germany) and 225 μl digestion solution
(0,5% SDS, 21 mM Tris–HCl). Paraffin-embedded tis-
sues were cut into sections. Approximately 1–1.5 cm2 of
sectioned tissue was put in 250 μL proteinase K diges-
tion solution. Digestions were performed in a thermo-
shaker at 55°C overnight at 1400 rpm. The subsequent
day DNA was extracted using a NucliSens EasyMAG
extraction system (bioMérieux, Boxtel, Netherlands). Sam-
ples were processed according to manufacturer’s instruc-
tions and eluted in 60 μL elution buffer. Ten μL of DNA
isolate was added to the PCR, which was performed as
previously described [15]. An internal control was added
to each sample before EasyMAG isolation and a real-time
PCR to detect the internal control target was run parallel
to the C. burnetii PCR to monitor DNA extraction and
PCR inhibition [15]. For cornea samples and paraffin-
embedded samples an additional PCR to detect human
albumin DNA was performed to ensure sufficient input
material in each PCR. Albumin PCR cycle threshold
values for cornea PCR’s varied from 19 to 20.3 and for
paraffin-embedded tissues from 26.4 to 28.9.
Data collection
Donor characteristics, such as age, gender, cause of
death, clinical characteristics, and place of residence
were recorded. Three criteria for increased geographical
risk of Q fever were applied. First, living in a four-digit
postal code area where at least one Q fever patient was
reported in the preceding 3 months. Second, living
within a five-kilometre radius of an infected farm, where
C. burnetii was detected in the bulk tank milk. Third,
living in a three-digit postal code area in which the Q
fever incidence was higher than 20/100.000 inhabitants
in any of the years 2007 to 2010. Approximately 15% of
the Dutch population lives in this area, where 86.6% of
the Q fever cases were reported. The data on Q fever in-
cidence were obtained from the Dutch National Institute
for Public Health and the Environment. The data on
bulk tank milk positive farms were obtained from the
Dutch Food and Consumer Product Safety Authority.
The five-kilometer radius from infected farms to the
residence of each donor was determined by measuring
the distance between both postal codes.
For all donors who tested positive for C. burnetii an-
tibodies, additional clinical, occupational, geographical
and -if available- histological data were gathered, to de-
termine the likelihood of previous infection with C. bur-
netii, and to establish the presence of signs of chronic Q
fever. Information was gathered by reviewing charts,
interviewing the general practitioner or next of kin and
by reviewing autopsy results and results of histological
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examination of remnant hearts after heart valve dona-
tion, if performed. Factors that were considered risk fac-
tors for chronic Q fever are heart valve disease, heart
valve or vascular prosthetics, aortic aneurysms and being
immunocompromised [16].
Ethics
Consent for donation, including testing for transmittable
infectious diseases, was obtained prior to donation from
either the donor, as registered in the Dutch donor regis-
try, or from the legal next of kin. Because of the Q fever
outbreak in The Netherlands the Dutch Health Advisory
board deemed additional testing for C. burnetii neces-
sary. Since consent for testing for transmittable infec-
tious diseases was obtained and all data were analysed
anonymized no specific approval by an Ethical Commit-
tee was needed for this study according to the Code of
Conduct for Health Research, as implemented by the
Dutch Federation of Biomedical Scientific Societies,
which is followed by the involved organisations.
Data analysis
All data were entered in a database and analysed with
the statistical software program SPSS 15.0 for Windows
(SPSS Inc., Chicago, IL). For statistical analysis of dif-
ferences between groups, ANOVA or Chi-squared tests




Between October 2010 and June 2011, 1033 consecutive
donors donated at least one approved tissue, and were
tested for IgG antibodies against phase 2 of C. burnetii.
The mean age of the included donors was 65.6 ± 12.3
years (range 0–85) and 664 (64.3%) of them were male.
950 Donors donated corneas (92.0%), 187 skin (18.1%),
139 heart valves (13.5%), 13 thoracic aortas (1.3%), and
86 musculoskeletal tissues (8.3%).
Thirty-three donors (3.2%) lived in a postal code area,
where in the previous three months a Q fever patient
had been reported. Eighty donors (7.7%) lived within a
five-kilometre radius of a previously contaminated farm,
and 147 (14.3%) donors lived in the high incidence Q
fever area.
Serological testing
Fifty of the 1033 donors (4.8%) tested positive for IgG
antibodies against phase 2 of C. burnetii by EIA. In
31 donors (3.0%) the reactivity was confirmed by IFA.
Twenty-four samples were reactive for both phase 1
and 2, while seven samples were only reactive for phase 2
IgG. One sample showed very high background fluo-
rescence with a few discernible bacteria and was scored
positive. One donor (0.1%) had IgG phase 1 and 2 titers of
both 1:4096 in the IFA, indicative for chronic Q fever [16].
There was a remarkable difference between the two kit
lots used for this study. 12/547 (2.2%) of the donors tested
(borderline) positive with the first kit lot (SBA.AG), while
38/486 (7.8%) tested positive with the second lot (SKA.
CD, p < 0.001). All donors for whom IgG reactivity was
not confirmed by IFA had been tested with the second lot.
Usually IFA is more sensitive [17]. Thus, it is seems highly
likely that the EIA results were false-positive. Spiking ex-
periments confirmed this (see Methods section). Compar-
ing signals from all measured samples showed elevated
background signals for lot SKA.CD and increased num-
bers of borderline and positive samples using this lot
(Figure 1).
These data suggest a problem with cross-reactivity
with unknown antigens leading to false-positive reactiv-
ity. Indeed, re-testing the 19 discordant samples with a
new lot that became available after the study showed ten
non-reactive, eight borderline and one positive sample in
this lot. Based on these results, we consider only donors
who tested positive in both EIA and IFA C. burnetii
seropositive.
PCR testing
For 29 of the 31 donors who tested positive in the EIA
and IFA one or more tissues were available for PCR test-
ing. For 2 donors the tissues were discarded after initial
assessment at the bank for quality reasons. The number
of available tissues for PCR testing and the results of
PCR testing are presented for each type of tissue in
Table 1. No Coxiella DNA was detected in any of the
samples.
Characteristics of donors who tested positive for
C. burnetii phase 2 IgG
The mean age in IFA-confirmed seropositive donors was
67.0 ± 9.9 years (range 46–83 years). In the age group
from 40–59 years 2.4% of the donors was seropositive,
in the group from 60–79 years 3.2% and in group from
80–85 years 3.9%. 22/31 seropositive donors were male
(71.0%). The donated tissues are shown in Table 1. Five
donors had risk factors for chronic Q fever, namely vas-
cular prosthesis (N = 1), heart valve disease (N = 1), ar-
tificial heart valve (N = 1), aortic dissection/aneurysm
(N = 2). None of these donors with risk factors for chro-
nic Q fever had a serological profile indicating chronic
disease, and in two donors autopsy was performed, which
showed no abnormalities. In four seropositive donors the
remnant hearts after heart valve donation were examined,
which resulted in identification of one donor with a focal
pericarditis. However, PCR testing of samples of the heart
of this donor did not reveal any C. burnetii DNA. The
donor who had a serological profile suspect for chronic Q
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fever was a male donor, 68 years old, who died of an acute
cardiac arrest due to a myocardial infarction. The donor
did not live in a high risk area for Q fever and had no
work related risk factors for Q fever, signs of past infection
or risk factors for chronic infection. No autopsy was per-
formed. He donated corneas and skin, which tested nega-
tive for C. burnetii DNA. No seropositive patients lived in
an area where in the last 13 weeks an acute Q fever pa-
tient had been reported, but 6 seropositive donors lived
within a five-kilometer radius of an infected farm. Eleven
donors (35.5%) lived in a high incidence Q fever area.
There was no significant difference in age between
groups of seropositive or seronegative donors. There was
no significant correlation between gender and seroposi-
tivity; the percentage of males was 71.0% in seropositive
versus 64.1% in seronegative donors, respectively. There
was no increased level of seropositivity in donors living
in areas where in the previous 13 weeks acute Q fever
patients had been reported or in donors living within a
five-kilometer radius from an infected farm. In contrast,
the percentage seropositivity was higher in donors living
in high incidence Q fever areas as compared to donors
living elsewhere (7.5% vs. 2.3%, P = 0.002).
Discussion
A few years after the large Q fever outbreaks in the
Netherlands, concern about potential transmission through
tissue transplantation is more focused on donors with si-
lently incubating chronic Q fever than on acute infections.
Risk assessments are hampered by limited knowledge
about the magnitude of the outbreaks. Although the out-
breaks have been studied extensively, most studies were
limited to the outbreak areas. To our knowledge, no
nation-wide data are available on the prevalence of anti-
bodies against Coxiella after the outbreaks, and our study





















Figure 1 Distribution of the anti-Coxiella phase 2 IgG signals observed with the two EIA kit lots used in this study. OD/CO = optical
density divided by the cutoff. Samples with OD/CO≥ 1 are considered positive. The borderline cutoff is lot-dependent and was 0.75 for lot SKA.
CD and 0.72 for lot SBA.AG.
Table 1 Results of PCR testing for the presence of C.




EIA and IFA positive N = 31
Donated tissues 28 6 5 4
Available for PCR testing 25 6 4 3
PCR negative 24 +1a 6 4b 3
Results of PCR testing for the presence of C. burnetii DNA in donated tissues in
donors who tested anti-Coxiella positive in EIA and IFA.
a+1 indicates that one test gave an invalid result due to inhibition of the PCR.
bFrom one patient no aortic valve and aortic wall tissue was available for
PCR testing.
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3.0% (31/1033 donors). It should be added that the cohort
may not be representative for the general population. The
seroprevalence of 3.0% is twice as high as the prevalence
prior to the series of outbreaks which was reported to be
1.5% in the general population, using the same EIA assay
[18] and would even be higher if only EIA reactivity was
considered (50/1033, 4.8%).
The seroprevalence was 7.5% (11/147 donors) in the
area with a high number of Q fever notifications (>20/
100.000 inhabitants during the outbreaks). The preva-
lence in this high-risk area is lower than the previously
reported 12% in healthy blood donors in the outbreak
area [14] and the 10.7% reported by a hospital in the
center of the outbreak [19]. In both cases the most likely
explanation for the lower prevalence found among tissue
donors is the definition of a larger high-risk area.
In the age group of most donors (40 and older) in
samples from 2006–2007 the prevalence was 2.1%. For
this age group, the difference with the seroprevalence
determined in this study is not significant. Prior to
the outbreaks, the anti-Coxiella seroprevalence in the
Netherlands was shown to increase with age [18]. A
likely explanation why age was not identified as a risk
factor for tissue donors is that few post-mortem tis-
sue donors are younger than 40, and during the out-
breaks it was unlikely that age affected the exposure
risk since Q fever is an airborne infection.
There was an unexpected difference in specificity be-
tween the two EIA kit lots used in this study. It is not
known whether the high number of false-positive reac-
tions observed with one lot was partly due to the cada-
veric nature of the specimens. The intended use of the
EIA is the detection of recent or chronic Coxiella infec-
tions and not the screening of donors, in whom the low
incidence intrinsically leads to a lower positive predictive
value. Tests used for screening of donors require a more
stringent batch release than regular in-vitro diagnostics
tests, but no Coxiella test is on the market for screening
purposes.
After acute Coxiella infection, DNA and antigen can
be detected for a long time in several tissues, in parti-
cular in bone marrow where even in the absence of se-
rological evidence for chronic infection, DNA can be
detected up to decades after infection [7,8]. Animal ex-
periments showed that the DNA-positive bone marrow
is not infectious in susceptible mice [8]. In contrast,
bone marrow from a patient with Q fever endocarditis
was infectious in guinea pigs [20]. We detected no
Coxiella DNA in any of the tissues available for PCR
testing. The 24 PCR-negative corneas confirmed ex-
pectations from a risk assessment that no bacteria are
present in corneas after infection with C. burnetii. For
skin, heart valves and bone marrow the numbers of
tested donors were quite small and no final conclusions
can be drawn. The current study contained only one
donor (0.1%) with a serological profile indicating chronic
Q fever. The cornea and skin samples of this donor did
not test positive for Coxiella DNA. It was not possible to
confirm the diagnosis any further since the donor was
deceased.
Our data show that the combination of the Serion EIA
and confirmation with IFA is an effective algorithm for
screening post-mortem samples from tissue donors. The
IFA test is considered the ‘golden standard’ for Q fever
diagnostics, and is more sensitive than the EIA [17]. The
EIA was chosen for the screening because it is less
labour-intensive and more convenient for screening lar-
ger numbers of samples. It is unlikely that the lower sen-
sitivity of the EIA (as compared to the IFA) increases the
risk of transplanting infected tissues, since all patients
suffering from chronic Coxiella infection show high IgG
titers, and the performance of the test during or shortly
after acute infection is excellent. The major disadvantage
of using a less sensitive screening test is that the preva-
lence of Q fever may be underestimated due to waning
of the IgG signal [18]. This underestimation will increase
over time, assuming no new outbreaks occur. With the
current study, that was undertaken at the end of/right
after the outbreak period, this underestimation is ex-
pected to be limited. An obvious advantage of a less sen-
sitive screening test is that fewer tissues will be rejected
based on screening results. Since Coxiella transmission
is not expected years after acute infection, using the EIA
as a screening method may provide the optimal balance
between safety and availability of donated tissues.
After the Q fever outbreaks in The Netherlands the
Health Council of the Netherlands advised to test tissue
donors donating tissues with a higher risk of transmis-
sion for contamination with C. burnetii [10]. Because of
the geographic spread with cases in almost the whole
country in the course of the outbreak, the screening was
performed nationwide. The necessity of a nationwide
screening was confirmed by the results of this current
study in which more than half of the seropositive donors
(17 of 31) lived outside the risk areas for Q fever. No
guideline was given by the Health Council as to when
testing of donors can be stopped. The interval between
initial infection and when chronic Q fever becomes
manifest is reported to be years [13]. Since the main
concern is transmission through tissues from donors
with chronic Q fever, it may be reasonable to stop test-
ing when the number of new chronic Q fever patients in
The Netherlands drops back to pre-outbreak levels.
Conclusions
This study provides a validated and effective test algo-
rithm that can be used for the screening of post-mortem
samples of tissue donors for antibodies against Coxiella
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burnetii. Furthermore, this study provides a first estimate
of 3.0% of the seroprevalence of antibodies against
Coxiella in the Dutch deceased tissue donor popula-
tion after the recent outbreaks of Q fever in The
Netherlands. The fact that all corneas from donors with
IgG reactivity tested negative for the presence of Coxiella
DNA confirmed expectations from a risk assessment that
no bacteria are present in corneas after infection with C.
burnetii. The data provided by this study can be used to
optimize the balance between safety and availability of do-
nated tissues.
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